Mogamulizumab (Anti-CCR4 / CD194)Mogamulizumab (Anti-CCR4 / CD194)
Move your mouse over image or click to enlarge

Mogamulizumab (Anti-CCR4 / CD194)

Mogamulizumab (Anti-CCR4 / CD194) is a defucosylated humanized recombinant monoclonal antibody targeting CCR4. Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL). MW:145.5 KD.
Cat# Size Price Qty Buy
A2568-1mg*25 1mg*25
£4,152.00
A2568-1mg*5 1mg*5
£1,384.00
A2568-1mg 1mg
£466.00

Additional Information

Property Value or Rating
Manufacturer Selleck Chemicals LLC
Manufacturer Cat# A2568

Related Documents